{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:13:02Z","timestamp":1789243982968,"version":"build-2803163510"},"reference-count":112,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR-12206-17"],"award-info":[{"award-number":["SCOR-12206-17"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA032102"],"award-info":[{"award-number":["CA032102"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA142509"],"award-info":[{"award-number":["CA142509"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA184464"],"award-info":[{"award-number":["CA184464"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA194264"],"award-info":[{"award-number":["CA194264"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2019,6,3]]},"DOI":"10.1080\/17425255.2019.1621839","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T03:29:01Z","timestamp":1558322941000},"page":"459-473","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma"],"prefix":"10.1080","volume":"15","author":[{"given":"Muhamed","family":"Baljevic","sequence":"first","affiliation":[{"name":",","place":["USA"]},{"name":"Fred & Pamela Buffett Cancer Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":",","place":["USA"]},{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"issue":"4","key":"e_1_3_4_3_1","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo A","year":"2001","unstructured":"Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001 Apr;86(4):399\u2013403. PubMed PMID: 11325646","journal-title":"Haematologica"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00111"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.817556"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1417388"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13285"},{"key":"e_1_3_4_12_1","unstructured":"Velcade (bortezomib). An overview of velcade and why it is authorised in the EU]. [cited 2019 Apr 4]. Available from: https:\/\/www.ema.europa.eu\/medicines\/human\/EPAR\/velcade"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_3_4_14_1","unstructured":"Kyprolis (carfilzomib). An overview of Kyprolis and why it is authorised in the EU]. [cited 2019 Apr 4]. Available from: https:\/\/www.ema.europa.eu\/medicines\/human\/EPAR\/kyprolis"},{"key":"e_1_3_4_15_1","unstructured":"Ninlaro (ixazomib). An overview of Ixazomib and why it is authorised in the EU]. [cited 2019 Apr 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ninlaro"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.04.006"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7732382"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201509092"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.11.007"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1959"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053263"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206"},{"issue":"11","key":"e_1_3_4_26_1","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams J","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615\u20132622. PubMed PMID: 10363983","journal-title":"Cancer Res"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00029-8"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0781"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.106"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23606"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1283-3"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0010-0"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002956"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005710"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx050313d"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1637-5"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2873"},{"issue":"8","key":"e_1_3_4_41_1","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian C","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002 Aug;8(8):2505\u20132511. PubMed PMID: 12171876","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18722"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00376-5"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.45.1746"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.039164"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-459883"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0822"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.047662"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.29"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212470388"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.212"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23387"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3007"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3352"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13296"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09232.x"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683854"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208272"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93602"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2766"},{"key":"e_1_3_4_75_1","unstructured":"NINLARO\u00ae (ixazomib) capsules. For oral use. Full prescribing information. Cambridge (MA): Takeda Pharmaceutical Company Limited; 2015 [cited 2007 Jul 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208462lbl.pdf"},{"key":"e_1_3_4_76_1","unstructured":"European Medicines Agency - Committee for Medicinal Products for Human Use. Assessment report. Ninlaro\u00ae[INN: ixazomib]. London: European Medicines Agency; 2016 [cited 2007 Jul 20]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003844\/WC500217623.pdf"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.719"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0526-4"},{"key":"e_1_3_4_80_1","article-title":"Clinical pharmacology of ixazomib: the first oral proteasome inhibitor","author":"Gupta N","unstructured":"Gupta N, Hanley MJ, Xia C, et al. Clinical pharmacology of ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet. 2019;58(4):431-449. PubMed PMID: 30117017","journal-title":"Clin Pharmacokinet"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12542"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12991"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0509-1"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14125"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548826"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548941"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717769"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"issue":"22","key":"e_1_3_4_89_1","doi-asserted-by":"crossref","first-page":"abstract 674","DOI":"10.1182\/blood.V128.22.674.674","article-title":"Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe francophone du my\u00e9lome (IFM)","volume":"128","author":"Moreau P, Hulin C","year":"2016","unstructured":"Moreau P, Hulin C, Caillot D, et al. Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe francophone du my\u00e9lome (IFM). Blood. 2016;128(22):abstract 674.","journal-title":"Blood"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15394"},{"issue":"23","key":"e_1_3_4_91_1","doi-asserted-by":"crossref","first-page":"abstract 3155","DOI":"10.1182\/blood.V126.23.3155.3155","article-title":"Phase II study of the combination of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma","volume":"126","author":"Shah JJ, Feng L","year":"2015","unstructured":"Shah JJ, Feng L, Weber D, et al. Phase II study of the combination of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma. Blood. 2015;126(23):abstract 3155.","journal-title":"Blood"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8068"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.013"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.10.075"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja058320b"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213009"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2616"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686378"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14113"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14987"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14498"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801329v"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243402"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.075226"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0327-x"},{"key":"e_1_3_4_107_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.V124.21.34.34","article-title":"Clinical profile of single-agent oprozomib in patients (Patients) with multiple myeloma (MM): updated results from amulticenter, open-label, dose escalation phase 1b\/2 study","volume":"124","author":"R SM V","year":"2014","unstructured":"R SM V, Siegel DS, Kaufman JL, et al. Clinical profile of single-agent oprozomib in patients (Patients) with multiple myeloma (MM): updated results from amulticenter, open-label, dose escalation phase 1b\/2 study. Blood. 2014;124:34.","journal-title":"Blood"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2397"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.56"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-849893"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.03.026"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2019.1621839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:02:13Z","timestamp":1770372133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2019.1621839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,3]]}},"alternative-id":["10.1080\/17425255.2019.1621839"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2019.1621839","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}